Product news

Share this article:
The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes. Amylin and Eli Lilly & Co., joint manufacturers of Byetta, will make labeling changes featuring more prominent warnings about the risk of acute hemorrhagic or necrotizing pancreatitis.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.